Advanced glycation end products and the kidney

被引:301
|
作者
Bohlender, JM [1 ]
Franke, S [1 ]
Stein, G [1 ]
Wolf, G [1 ]
机构
[1] Univ Klin Jena, Innere Med Klin 3, Dept Internal Med 3, Jena, Germany
关键词
RAGE; diabetic nephropathy; progression of renal disease; inflammation; glycoxidation;
D O I
10.1152/ajprenal.00398.2004
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Advanced glycation end products (AGEs) are a heterogeneous group of protein and lipids to which sugar residues are covalently bound. AGE formation is increased in situations with hyperglycemia ( e. g., diabetes mellitus) and is also stimulated by oxidative stress, for example in uremia. It appears that activation of the renin-angiotensin system may contribute to AGE formation through various mechanisms. Although AGEs could nonspecifically bind to basement membranes and modify their properties, they also induce specific cellular responses including the release of profibrogenic and proinflammatory cytokines by interacting with the receptor for AGE ( RAGE). However, additional receptors could bind AGEs, adding to the complexity of this system. The kidney is both: culprit and target of AGEs. A decrease in renal function increases circulating AGE concentrations by reduced clearance as well as increased formation. On the other hand, AGEs are involved in the structural changes of progressive nephropathies such as glomerulosclerosis, interstitial fibrosis, and tubular atrophy. These effects are most prominent in diabetic nephropathy, but they also contribute to renal pathophysiology in other nondiabetic renal diseases. Interference with AGE formation has therapeutic potential for preventing the progression of chronic renal diseases, as shown from data of animal experiments and, more recently, the first clinical trials.
引用
收藏
页码:F645 / F659
页数:15
相关论文
共 50 条
  • [41] Dietary Advanced Glycation End Products and Aging
    Luevano-Contreras, Claudia
    Chapman-Novakofski, Karen
    NUTRIENTS, 2010, 2 (12) : 1247 - 1265
  • [42] Advanced glycation end products in clinical nephrology
    Kalousová, M
    Zima, T
    Tesar, V
    Stípek, S
    Sulková, S
    KIDNEY & BLOOD PRESSURE RESEARCH, 2004, 27 (01): : 18 - 28
  • [43] Toxicity of advanced glycation end products (Review)
    Kuzan, Aleksandra
    BIOMEDICAL REPORTS, 2021, 14 (05)
  • [44] ADVANCED GLYCATION END PRODUCTS IN ATOPIC DERMATITIS
    Hong, Jun Ki
    Hong, Ji Yeon
    Koh, Young Gue
    Park, Kui Young
    Seo, Seong Jun
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 16 - 16
  • [45] Advanced Glycation End Products in Neurodegenerative Diseases
    Raghavan, Cibin T.
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2024, 74 (04)
  • [46] Advanced glycation and glycoxidation end products in bone
    Wang, Bowen
    Vashishth, Deepak
    BONE, 2023, 176
  • [47] Chemistry and pathobiology of advanced glycation end products
    Schleicher, ED
    Bierhaus, A
    Häring, HU
    Nawroth, PP
    Lehmann, R
    ADVANCED GLYCATION END PRODUCTS IN NEPHROLOGY, 2001, 131 : 1 - 9
  • [48] Advanced glycation end-products and atherosclerosis
    Vlassara, H
    ANNALS OF MEDICINE, 1996, 28 (05) : 419 - 426
  • [49] The Chemistry of Advanced Glycation End-products
    Torres, Natalia M. P. de O.
    Xavier, Jadriane de A.
    Goulart, Marilia O. F.
    Alves, Rosemeire B.
    de Freitas, Rossimiriam P.
    REVISTA VIRTUAL DE QUIMICA, 2018, 10 (02) : 375 - 392
  • [50] Advanced Glycation End Products and Cardiovascular Disease
    Peppa, Melpomeni
    Raptis, Sotirios A.
    CURRENT DIABETES REVIEWS, 2008, 4 (02) : 92 - 100